The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced significant risk . Investors are now assessing the effect of generic competition , s